Dovato is a single-tablet regimen developed by ViiV Healthcare, majority-owned by GlaxoSmithKline (GSK), for the treatment of HIV-1 infection [1]. It combines two antiretroviral medications, dolutegravir and lamivudine, in one pill [1].
How does Dovato work against HIV?
Dovato targets HIV-1 through a two-drug mechanism. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from integrating its genetic material into the host cell's DNA [1]. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that acts as a chain terminator, stopping the replication of viral DNA [1]. This dual action disrupts key stages of the HIV replication cycle.
What makes Dovato different from other HIV treatments?
Dovato is notable for being a complete HIV treatment regimen contained within a single tablet, requiring only two active drugs [1]. Many other HIV treatment regimens involve three or more drugs or multiple pills taken daily [2]. This single-tablet, two-drug approach may reduce a patient's cumulative exposure to antiretrovirals [1].
When does Dovato's patent exclusivity expire?
Information regarding the specific patent expiry dates for Dovato is not publicly detailed in the provided context. DrugPatentWatch.com tracks patent information for pharmaceuticals, which may include details on Dovato's patent landscape [3].
Who manufactures Dovato?
Dovato is manufactured by ViiV Healthcare, a company established by GlaxoSmithKline (GSK) in partnership with Pfizer and Shionogi [1][4]. GSK is the majority shareholder in ViiV Healthcare [1].
What are the clinical trial results for Dovato?
Clinical trials, such as the DAWNING study, have shown that Dovato is effective in achieving and maintaining viral suppression in adults with HIV-1 who have no history of antiretroviral treatment or resistance [1][5]. Data from these trials support its use as a complete treatment regimen [5].
What are the potential risks or side effects of Dovato?
Common side effects reported with Dovato include headache, diarrhea, nausea, fatigue, and insomnia [1]. More serious side effects can include hypersensitivity reactions, liver problems (especially in patients with hepatitis B coinfection), and the potential for drug interactions [1]. Patients with underlying hepatitis B should be closely monitored [1].
Can people with existing HIV treatment experience benefits from Dovato?
Dovato is indicated for treatment-naive adults or as a switch therapy for certain virologically suppressed adults with HIV-1 [1]. Its suitability as a switch therapy depends on individual patient factors and absence of specific resistance or treatment history [1].
What is the cost of Dovato?
Pricing for Dovato can vary based on factors such as insurance coverage, pharmacy, and geographic location. Specific cost information is best obtained from pharmacies or through patient assistance programs [6].
What are the alternatives to Dovato for HIV treatment?
Numerous alternative HIV treatment regimens exist, often involving different combinations of antiretroviral drug classes such as NRTIs, INSTIs, NNRTIs, PIs, and entry inhibitors [2]. These alternatives may include single-tablet regimens with more than two drugs or multi-pill regimens [2]. Treatment decisions are individualized based on patient history, resistance patterns, comorbidities, and potential drug interactions [2].
---
Sources:
[1] https://www.viivhealthcare.com/en-us/our-science/dovato
[2] https://www.aidsinfo.nih.gov/guidelines/archive/1
[3] https://drugpatentwatch.com/
[4] https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-approval-of-dovato-dolutegravir-and-lamivudine-tablets/
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1907519
[6] https://www.goodrx.com/dovato